Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30595% above fair value
$228.44+7.61 (+3.45%)
Close on Nov 3, 2026Market cap $91.20BP/E –Yield –
Moderna Finance lease right-of-use assets, gross by Quarter
Finance lease right-of-use assets, gross ($M) ($M)
Moderna Finance lease right-of-use assets, gross: $132M in Q2 2026, unchanged from a year earlier.
Latest, Q2 2026
132
Period ended Jun 30, 2026
Change on a year earlier
0.0%
132 in Q2 2025
History
24 quarters
Since Q4 2019
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 8 (Balance Sheet Details).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finance lease right-of-use assets, gross ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 132 | 0.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 132 | 0.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 132 | 0.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 132 | -78.1% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 132 | -75.0% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 132 | -75.0% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 132 | -75.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 604 | -55.8% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 529 | -67.6% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 529 | -65.2% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 529 | -66.5% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,367 | -13.8% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,631 | +81.6% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,521 | +59.9% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,581 | +84.5% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,585 | +190.3% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 898 | +64.8% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 951 | +780.6% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 857 | +1,430.4% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 546 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 545 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 108 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 56 | +471.4% | Form 10-K (filed 2022-02-25) ↗ |
| Q4 2019 | Dec 31, 2019 | 9.80 | – | Form 10-K (filed 2021-02-26) ↗ |
Cite this data
StockData. (2026). Moderna Finance lease right-of-use assets, gross ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ppe-gross-fin-rou
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.
See a number that looks wrong?